Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.

Kumar R, Malla P, Kumar M.

Expert Opin Drug Discov. 2013 Aug;8(8):1013-27. doi: 10.1517/17460441.2013.797960. Review.

PMID:
23662859
2.

Trends in the development of new drugs for treatment of benign prostatic hyperplasia.

Kulig K, Malawska B.

Curr Med Chem. 2006;13(28):3395-416. Review.

PMID:
17168713
3.

Emerging drug therapies for benign prostatic hyperplasia.

Bullock TL, Andriole GL Jr.

Expert Opin Emerg Drugs. 2006 Mar;11(1):111-23. Review.

PMID:
16503830
4.

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.

Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J.

J Urol. 2013 Aug;190(2):615-9. doi: 10.1016/j.juro.2013.03.024.

PMID:
23499746
5.

The role of combination medical therapy in benign prostatic hyperplasia.

Greco KA, McVary KT.

Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Review.

PMID:
19002123
6.

Benign prostatic hyperplasia - progress in pathophysiology and management.

Dobrek Ł, Thor PJ.

Pol Merkur Lekarski. 2015 Nov;39(233):263-70.

PMID:
26637089
8.

[Benign prostatic hyperplasia medical treatment: systematic review of the literature by the CTMH/AFU].

Robert G, Descazeaud A, Delongchamps NB, Cornu JN, Azzouzi AR, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Saussine C, de la Taille A; Comité des troubles mictionnels de l’homme de l’Association française d’urologie..

Prog Urol. 2012 Jan;22(1):7-12. doi: 10.1016/j.purol.2011.07.009. Review. French.

PMID:
22195999
9.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
10.

[Benign prostatic hyperplasia: medical therapy].

Schlenker B, Gratzke C, Weidlich P, Seitz M, Reich O, Stief CG.

MMW Fortschr Med. 2007 Aug 16;149(33-34):29-31; quiz 32. Review. German.

PMID:
17912863
11.

Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.

Kumar VL, Wahane VD.

Indian J Med Sci. 2008 Apr;62(4):167-75. Review.

12.

Benign prostatic hyperplasia: an insight into current investigational medical therapies.

Tiwari A, Krishna NS, Nanda K, Chugh A.

Expert Opin Investig Drugs. 2005 Nov;14(11):1359-72. Review.

PMID:
16255676
13.

Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.

Elterman DS, Lawrentschuk N, Guns E, Hersey K, Adomat H, Wood CA, Fleshner N.

J Urol. 2010 May;183(5):2085-9. doi: 10.1016/j.juro.2009.12.097.

PMID:
20303529
14.

Pharmacotherapy and herbal treatment of benign prostatic hyperplasia.

Sun J, Zhang X.

Front Biosci (Landmark Ed). 2014 Jan 1;19:789-97. Review.

PMID:
24389223
15.

[Pharmacological treatment of benign prostatic hyperplasia].

Oelke M, Kuczyk MA, Herrmann TR.

Urologe A. 2009 Nov;48(11):1365-75; quiz 1376-7. doi: 10.1007/s00120-009-2141-y. German.

PMID:
19851747
16.
17.

Risk stratification for benign prostatic hyperplasia (BPH) treatment.

Emberton M, Fitzpatrick JM, Rees J.

BJU Int. 2011 Mar;107(6):876-80. doi: 10.1111/j.1464-410X.2010.10041.x. Review.

18.

Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.

Tarter TH, Vaughan ED Jr.

Curr Pharm Des. 2006;12(7):775-83. Review.

PMID:
16515494
19.

alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.

Thiyagarajan M.

Pharmacology. 2002 Jul;65(3):119-28. Review.

PMID:
12037374
20.

Benign prostatic hyperplasia: current clinical practice.

Djavan B, Eckersberger E, Finkelstein J, Espinosa G, Sadri H, Brandner R, Shah O, Lepor H.

Prim Care. 2010 Sep;37(3):583-97, ix. doi: 10.1016/j.pop.2010.04.004. Review.

PMID:
20705200
Items per page

Supplemental Content

Support Center